Next Article in Journal
Autochthonous Peruvian Natural Plants as Potential SARS-CoV-2 Mpro Main Protease Inhibitors
Next Article in Special Issue
Heparin Precursors with Reduced Anticoagulant Properties Retain Antiviral and Protective Effects That Potentiate the Efficacy of Sofosbuvir against Zika Virus Infection in Human Neural Progenitor Cells
Previous Article in Journal
Leveraging Hot Spots of TEAD–Coregulator Interactions in the Design of Direct Small Molecule Protein-Protein Interaction Disruptors Targeting Hippo Pathway Signaling
Previous Article in Special Issue
Heparin Mimetics and Their Impact on Extracellular Matrix Protein Assemblies
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Heparin, Low Molecular Weight Heparin, and Non-Anticoagulant Derivatives for the Treatment of Inflammatory Lung Disease

School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth PO1 2UP, UK
Pharmaceuticals 2023, 16(4), 584; https://doi.org/10.3390/ph16040584
Submission received: 22 February 2023 / Revised: 6 April 2023 / Accepted: 7 April 2023 / Published: 13 April 2023

Abstract

Unfractionated heparin has multiple pharmacological activities beyond anticoagulation. These anti-inflammatory, anti-microbial, and mucoactive activities are shared in part by low molecular weight and non-anticoagulant heparin derivatives. Anti-inflammatory activities include inhibition of chemokine activity and cytokine synthesis, inhibitory effects on the mechanisms of adhesion and diapedesis involved in neutrophil recruitment, inhibition of heparanase activity, inhibition of the proteases of the coagulation and complement cascades, inhibition of neutrophil elastase activity, neutralisation of toxic basic histones, and inhibition of HMGB1 activity. This review considers the potential for heparin and its derivatives to treat inflammatory lung disease, including COVID-19, ALI, ARDS, cystic fibrosis, asthma, and COPD via the inhaled route.
Keywords: heparin; inflammation; coagulation; COVID-19; ALI; ARDS; cystic fibrosis; asthma; COPD heparin; inflammation; coagulation; COVID-19; ALI; ARDS; cystic fibrosis; asthma; COPD

Share and Cite

MDPI and ACS Style

Shute, J.K. Heparin, Low Molecular Weight Heparin, and Non-Anticoagulant Derivatives for the Treatment of Inflammatory Lung Disease. Pharmaceuticals 2023, 16, 584. https://doi.org/10.3390/ph16040584

AMA Style

Shute JK. Heparin, Low Molecular Weight Heparin, and Non-Anticoagulant Derivatives for the Treatment of Inflammatory Lung Disease. Pharmaceuticals. 2023; 16(4):584. https://doi.org/10.3390/ph16040584

Chicago/Turabian Style

Shute, Janis Kay. 2023. "Heparin, Low Molecular Weight Heparin, and Non-Anticoagulant Derivatives for the Treatment of Inflammatory Lung Disease" Pharmaceuticals 16, no. 4: 584. https://doi.org/10.3390/ph16040584

APA Style

Shute, J. K. (2023). Heparin, Low Molecular Weight Heparin, and Non-Anticoagulant Derivatives for the Treatment of Inflammatory Lung Disease. Pharmaceuticals, 16(4), 584. https://doi.org/10.3390/ph16040584

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop